A Ribose-crosslinked Collagen Filler Treatment for Facial Lipoatrophy Associated With the Treatment of Human Immunodeﬁciency Virus
December 2008 | Volume 7 | Issue 12 | Case Reports | 1169 | Copyright © December 2008
Natalie Reytan MD, Berthold Rzany MD ScM
Objective: To report on the experience using a ribose-crosslinked collagen ﬁ ller in the treatment of a patient with HIV-associated facial lipoatrophy. Physician observations and photographs for documentation were collected up to 14 months posttreatment.
Methods: A patient with HIV with facial lipoatrophy was treated with the ribose-crosslinked collagen injectable ﬁ ller derived from por- cine collagen.
Results: After 4 treatment sessions over 7 months signiﬁ cant improvement was found and dermal thickening was retained in the area of the cheeks for an additional 7 months.
Conclusion: As facial lipoatrophy is a very stigmatizing manifestation of HIV, volume augmentation is highly beneﬁ cial. By using a ribose- crosslinked collagen, a very natural outcome was obtained that lasted for over 7 months. Additional studies should be conducted to further investigate the use of this ﬁ ller in the treatment of HIV-associated facial lipoatrophy.